Die direkten und indirekten Kosten der Schizophrenie

authored by

Werner Kissling, J. Höffler, Ute Seemann, P. Müller, E. Rüther, U. Trenckmann, Andrea Über, J. M. Graf, Petra Glaser, Th Glaser, O. Mast, Dorothee Schmidt

Abstract

In the present study the costs of schizophrenia in Germany were studied using the 'bottom up' prevalence-based method. In a random sample of 180 schizophrenic patients stratified according to the most important care institutions, direct and indirect costs were retrospectively documented for a 12-month period. Depending on the place of recruitment and the extent of care provided, total yearly costs result between about DM 33,000 for a patient treated predominantly on an outpatient basis and about DM 126,000 for a patient requiring hospital care and about DM 135,000 for a patient in job rehabilitation. The direct yearly treatment costs were, as expected, lowest for patients recruited in the private practice of a psychiatrist anti predominantly treated on an outpatient basis (DM 5,788), and were the highest in the psychiatric hospital (DM 64,661) and in job rehabilition (DM 79,996). In the patients recruited in the outpatient domain, doctors' fees and medication together were responsible for only 4.5% of the total costs, whereas the indirect costs (e.g. through work incapacity) were responsible for 87% of the total yearly costs. For methodological reasons the total costs caused by schizophrenic psychoses in Germany per year can at present be estimated only roughly. A conservative estimate is between 8.5 and 18 billion DM per year. The study shows that schizophrenia is a very expensive illness, the direct and indirect costs of which are on the whole comparable to those of the common somatic illnesses. Therefore, also for economical reasons, sufficient financial means should be invested in the research and treatment of this severe illness.

Organisation(s)

Institute of Health Economics

External Organisation(s)

Technical University of Munich (TUM)
Hans-Prinzhorn-Klinik (HPK)
University of Göttingen
Eli Lilly and Company
Bayer Vital GmbH
Janssen-Cilag GmbH

Type

Article

Journal

Fortschritte der Neurologie Psychiatrie

Volume

67

Pages

29-36

No. of pages

8

ISSN

0720-4299

Publication date

01.1999

Publication status

Published

Peer reviewed

Yes

ASJC Scopus subject areas

Neurology, Clinical Neurology, Psychiatry and Mental health

Sustainable Development Goals

SDG 3 - Good Health and Well-being

Electronic version(s)

https://doi.org/10.1055/s-2007-993735 (Access: Closed)